1. MGRM received CDSCO approval for its mBôs TKA system clinical trial in India. 2. Patient enrollment begins soon; first surgeries expected within 90 days.
Approval for clinical trials often leads to increased investor confidence and potential future revenue, similar to historical cases where regulatory approvals positively impacted biotech stocks.
The trial milestone and collaboration with Shalby can significantly influence MGRM’s market perception and stock performance.
Anticipation of immediate patient enrollment and surgeries contributes to short-term price movements.